Bryan K. Kee

3.0k total citations
78 papers, 1.3k citations indexed

About

Bryan K. Kee is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Bryan K. Kee has authored 78 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 30 papers in Cancer Research and 28 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Bryan K. Kee's work include Colorectal Cancer Treatments and Studies (53 papers), Cancer Genomics and Diagnostics (30 papers) and Genetic factors in colorectal cancer (24 papers). Bryan K. Kee is often cited by papers focused on Colorectal Cancer Treatments and Studies (53 papers), Cancer Genomics and Diagnostics (30 papers) and Genetic factors in colorectal cancer (24 papers). Bryan K. Kee collaborates with scholars based in United States, Thailand and Japan. Bryan K. Kee's co-authors include Cathy Eng, Michael J. Overman, Scott Kopetz, Arvind Dasari, Van K. Morris, Christopher R. Garrett, Robert A. Wolff, David R. Fogelman, Dipen M. Maru and Nishin A. Bhadkamkar and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Bryan K. Kee

73 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bryan K. Kee United States	19	967	496	489	419	365	78	1.3k
Claudia Maggi Italy	21	873 0.9×	301 0.6×	332 0.7×	261 0.6×	360 1.0×	36	1.3k
Ernesto Wasserman United States	17	812 0.8×	377 0.8×	114 0.2×	418 1.0×	358 1.0×	35	1.2k
David Páez Spain	20	828 0.9×	265 0.5×	162 0.3×	559 1.3×	292 0.8×	75	1.3k
Eiji Shinozaki Japan	21	1.4k 1.4×	528 1.1×	438 0.9×	309 0.7×	802 2.2×	172	1.9k
Chiara Pierantoni Italy	16	809 0.8×	245 0.5×	154 0.3×	340 0.8×	366 1.0×	40	1.3k
Elena Maccaroni Italy	17	545 0.6×	287 0.6×	138 0.3×	247 0.6×	299 0.8×	54	944
Hongnan Mo China	17	1.0k 1.0×	341 0.7×	148 0.3×	372 0.9×	427 1.2×	54	1.5k
Wataru Okamoto Japan	23	1.2k 1.2×	375 0.8×	402 0.8×	555 1.3×	777 2.1×	97	1.8k
Denise D. Tsao‐Wei United States	5	817 0.8×	181 0.4×	329 0.7×	558 1.3×	265 0.7×	7	1.4k
Diana L. Hanna United States	17	600 0.6×	258 0.5×	182 0.4×	238 0.6×	250 0.7×	75	1.0k

Countries citing papers authored by Bryan K. Kee

Since Specialization

Citations

This map shows the geographic impact of Bryan K. Kee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan K. Kee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan K. Kee more than expected).

Fields of papers citing papers by Bryan K. Kee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bryan K. Kee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan K. Kee. The network helps show where Bryan K. Kee may publish in the future.

Co-authorship network of co-authors of Bryan K. Kee

This figure shows the co-authorship network connecting the top 25 collaborators of Bryan K. Kee. A scholar is included among the top collaborators of Bryan K. Kee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bryan K. Kee. Bryan K. Kee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yousef, Abdelrahman, Saikat Chowdhury, Michael J. Overman, et al.. (2025). BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy. npj Precision Oncology. 9(1). 38–38. 1 indexed citations

Folkert, Ian W., Reza J. Mehran, Van K. Morris, et al.. (2025). Hepatectomy Plus Chemotherapy or Chemotherapy Alone for Resectable Liver and Unresectable Lung Metastases from Colorectal Adenocarcinoma (LUNA): A Randomized Phase II Trial. Annals of Surgical Oncology. 33(4). 2899–2907.

Thomas, Jane V., Kaysia Ludford, Jason Willis, et al.. (2023). Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Research Communications. 3(12). 2510–2517. 4 indexed citations

Napolitano, Stefania, Aparna R. Parikh, Jason T. Henry, et al.. (2023). Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing. JCO Precision Oncology. 7(7). e2300228–e2300228. 1 indexed citations

Piha‐Paul, Sarina A., Chieh Tseng, Hai T. Tran, et al.. (2023). A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemotherapy and Pharmacology. 92(2). 107–118. 4 indexed citations

Morris, Van K., Bryan K. Kee, Michael J. Overman, et al.. (2022). Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. Journal of Gastrointestinal Oncology. 13(2). 647–656. 2 indexed citations

Rogers, Jane E., Terri L. Woodard, Arvind Dasari, et al.. (2021). Fertility discussions in young adult stage III colorectal cancer population: a single-center institution experience. Supportive Care in Cancer. 29(12). 7351–7354. 7 indexed citations

Advani, Shailesh, Michael D. Swartz, Jonathan M. Loree, et al.. (2020). Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clinical Colorectal Cancer. 20(2). 137–147.e1. 25 indexed citations

Advani, Shailesh, Michael J. Overman, Jonathan M. Loree, et al.. (2019). Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 19(1). 48–56.e2. 2 indexed citations

10.

Sarshekeh, Amir Mehrvarz, Shailesh Advani, Michael J. Overman, et al.. (2017). Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS ONE. 12(3). e0173345–e0173345. 64 indexed citations

11.

Tsimberidou, Apostolia M., David S. Hong, Carrie Cartwright, et al.. (2017). Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson precision medicine study.. Journal of Clinical Oncology. 35(15_suppl). 2513–2513. 12 indexed citations

12.

Overman, Michael J., L. Adam, Kanwal Raghav, et al.. (2017). Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Annals of Oncology. 29(1). 139–144. 41 indexed citations

13.

Morelli, Maria Pia, Michael J. Overman, Arvind Dasari, et al.. (2015). Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Annals of Oncology. 26(4). 731–736. 186 indexed citations

14.

Morris, Van K., Michael J. Overman, Zhi-Qin Jiang, et al.. (2014). Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer. Clinical Colorectal Cancer. 13(3). 164–171. 93 indexed citations

15.

Kopetz, Scott, Michael J. Overman, Ken Chen, et al.. (2014). Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 32(15_suppl). 3509–3509. 18 indexed citations

16.

Tanasanvimon, Suebpong, Naveen Garg, Chitra Viswanathan, et al.. (2013). High prevalence of recurrent thrombosis in subsets of cancer patients with isolated gonadal vein thrombosis: A single center retrospective study. Thrombosis Research. 133(2). 154–157. 9 indexed citations

17.

Şahin, İbrahim Halil, et al.. (2013). Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature. Journal of Cancer. 4(4). 320–322. 55 indexed citations

18.

Garrett, Christopher R., Hesham M. Hassabo, Nishin A. Bhadkamkar, et al.. (2012). Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. British Journal of Cancer. 106(8). 1374–1378. 124 indexed citations

19.

Garrett, Christopher R., Ben George, Chitra Viswanathan, et al.. (2012). Survival Benefit Associated With Surgical Oophorectomy in Patients With Colorectal Cancer Metastatic to the Ovary. Clinical Colorectal Cancer. 11(3). 191–194. 19 indexed citations

20.

Arnold, Susanne M., John J. Rinehart, Eleftheria Tsakalozou, et al.. (2010). A Phase I Study of 7- t -Butyldimethylsilyl-10-Hydroxycamptothecin in Adult Patients with Refractory or Metastatic Solid Malignancies. Clinical Cancer Research. 16(2). 673–680. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact